Ronsheim Matthew
- SEC CIK
- 0001824386
No open-market purchases or sales filed in the past year.
Current role at each company
- INVA Innoviva, Inc.See Remarksas of May 21, 2024
- ETTX Entasis Therapeutics Holdings Inc.Chief of Pharma Sciences & MFGas of Jul 11, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Ronsheim Matthew as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
ETTX Entasis Therapeutics Holdings Inc.
Chief of Pharma Sciences & MFG1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 20, 2021 (view filing) | Oct 19 | 1 day | Ronsheim MatthewSee Remarks | SSale | −3.76K | $3.19 | −$12.0K | −7.5%46.2K after |